跳至主要内容
临床试验/CTRI/2019/10/021533
CTRI/2019/10/021533尚未招募未知

Clinical Pharmacogenomics study of Imatinib in Chronic Myeloid Leukaemia patients

R Saravanabhavan0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
尚未招募
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

入选标准

  • Patients who are already under the treatment for Chronic Myeloid Leukaemia
  • Patients of both male and female sexes are included
  • Age range of the patients should be 18 to 85 should have completed 18 years before taking part in the study
  • Patients in any stage of the CML are included

排除标准

  • Patients with concurrent malignancies other than CML
  • 2. A serious uncontrolled medical disorder that would impair the ability of the subjects to receive therapy. Hence, patients with any of the following diseases other than CML who are considered not suitable by the physician will not be recruited for this research project:
  • Cardiovascular Disease Fluid Retention, Bone Marrow suppression
  • Gastrointestinal Disorders Hepatic Impairment Hypothyroidism
  • Renal Impairmen
  • Patients treated with any other chemotherapeutic drugs in addition to imatinib
  • Female patients who are pregnant
  • Patients who have not completed 18 years of age

研究者

发起方
R Saravanabhavan

相似试验